JP7753348B2 - ヒトモノカルボン酸トランスポーター１抗体及びその使用 - Google Patents

ヒトモノカルボン酸トランスポーター１抗体及びその使用

Info

Publication number
JP7753348B2
JP7753348B2 JP2023515671A JP2023515671A JP7753348B2 JP 7753348 B2 JP7753348 B2 JP 7753348B2 JP 2023515671 A JP2023515671 A JP 2023515671A JP 2023515671 A JP2023515671 A JP 2023515671A JP 7753348 B2 JP7753348 B2 JP 7753348B2
Authority
JP
Japan
Prior art keywords
seq
antibody
comprises seq
antigen
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542639A (ja
Inventor
チャールズ ドーシー，フランク
ベンジャミン グランジャー，ジョセフ
ウラジーミロヴナ ルツォバ，キーラ
シュレーダー，オリヴァー
ワン，ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunometabolism Development Company LLC
Original Assignee
Immunometabolism Development Company LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunometabolism Development Company LLC filed Critical Immunometabolism Development Company LLC
Publication of JP2023542639A publication Critical patent/JP2023542639A/ja
Priority to JP2025165282A priority Critical patent/JP2026004435A/ja
Application granted granted Critical
Publication of JP7753348B2 publication Critical patent/JP7753348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023515671A 2021-09-14 2022-09-14 ヒトモノカルボン酸トランスポーター１抗体及びその使用 Active JP7753348B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025165282A JP2026004435A (ja) 2021-09-14 2025-10-01 ヒトモノカルボン酸トランスポーター１抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US63/261,177 2021-09-14
US202163272903P 2021-10-28 2021-10-28
US63/272,903 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025165282A Division JP2026004435A (ja) 2021-09-14 2025-10-01 ヒトモノカルボン酸トランスポーター１抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2023542639A JP2023542639A (ja) 2023-10-11
JP7753348B2 true JP7753348B2 (ja) 2025-10-14

Family

ID=83558178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023515671A Active JP7753348B2 (ja) 2021-09-14 2022-09-14 ヒトモノカルボン酸トランスポーター１抗体及びその使用
JP2025165282A Pending JP2026004435A (ja) 2021-09-14 2025-10-01 ヒトモノカルボン酸トランスポーター１抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025165282A Pending JP2026004435A (ja) 2021-09-14 2025-10-01 ヒトモノカルボン酸トランスポーター１抗体及びその使用

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509822A (ja) 2018-01-05 2021-04-08 イミューンネクスト・インコーポレイテッドＩｍｍｕｎｅｘｔ，Ｉｎｃ． 抗ｍｃｔ１抗体およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509822A (ja) 2018-01-05 2021-04-08 イミューンネクスト・インコーポレイテッドＩｍｍｕｎｅｘｔ，Ｉｎｃ． 抗ｍｃｔ１抗体およびその使用

Also Published As

Publication number Publication date
TWI842088B (zh) 2024-05-11
KR20240053656A (ko) 2024-04-24
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
CA3230072A1 (en) 2023-03-23
DOP2024000049A (es) 2024-06-16
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JOP20240054A1 (ar) 2024-03-13
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20230340155A1 (en) Antibodies that Specifically Bind PD-1 and Methods of Use
US20190048089A1 (en) Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
US20180355043A1 (en) Antibodies Specifically Binding HLA-DR and Their Uses
EP3708227A1 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
US20210269520A1 (en) Anti-human cd19 antibodies
CA2769464C (en) Humanized anti-amyloid-.beta. oligomer antibody
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
JP2026004435A (ja) ヒトモノカルボン酸トランスポーター１抗体及びその使用
US20250059285A1 (en) Galectin-10 antibodies
CN120641442A (zh) Btla激动剂抗体及其用途
CN118043353A (zh) 人单羧酸转运蛋白1抗体及其用途
JP2025539796A (ja) Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体
BR122024021001A2 (pt) Moléculas de ligação que multimerizam cd45, vetores, composição farmacêutica compreendendo as moléculas e uso
EA052830B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ДОМЕН γC ФИБРИНА ИЛИ ФИБРИНОГЕНА ЧЕЛОВЕКА, И СПОСОБЫ ПРИМЕНЕНИЯ
EA040943B1 (ru) Антитела к cd154 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230417

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251001

R150 Certificate of patent or registration of utility model

Ref document number: 7753348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150